Keybank National Association OH Has $52.39 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Keybank National Association OH increased its position in Illumina, Inc. (NASDAQ:ILMN) by 52.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 392,014 shares of the life sciences company’s stock after buying an additional 134,862 shares during the period. Keybank National Association OH owned 0.25% of Illumina worth $52,385,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. First Trust Direct Indexing L.P. raised its holdings in shares of Illumina by 23.6% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 2,685 shares of the life sciences company’s stock worth $350,000 after purchasing an additional 512 shares during the period. Stephens Inc. AR grew its position in Illumina by 21.5% in the third quarter. Stephens Inc. AR now owns 6,533 shares of the life sciences company’s stock worth $852,000 after acquiring an additional 1,156 shares in the last quarter. Gladstone Institutional Advisory LLC grew its stake in shares of Illumina by 30.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 3,843 shares of the life sciences company’s stock valued at $501,000 after buying an additional 895 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Illumina by 73.3% in the third quarter. Janney Montgomery Scott LLC now owns 6,580 shares of the life sciences company’s stock worth $858,000 after purchasing an additional 2,783 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its stake in Illumina by 74.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 276,506 shares of the life sciences company’s stock worth $36,059,000 after buying an additional 117,730 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ILMN. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Canaccord Genuity Group lowered their price target on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Robert W. Baird lifted their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. increased their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average target price of $155.45.

Illumina Trading Down 5.1 %

Shares of ILMN stock opened at $84.20 on Tuesday. The firm has a 50-day moving average price of $122.36 and a 200 day moving average price of $132.81. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $13.34 billion, a P/E ratio of -10.96, a P/E/G ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 12-month low of $83.79 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.